• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

GALECTIN THERAPEUTICS INC.

Notes

No. Proposition For Against Abstain
1

DIRECTOR Gilbert F. Amelio, Ph.D

2

DIRECTOR Benjamin S Carson Sr MD

3

DIRECTOR Kary Eldred

4

DIRECTOR Kevin D. Freeman

5

DIRECTOR Joel Lewis

6

DIRECTOR Gilbert S. Omenn, M.D.

7

DIRECTOR Marc Rubin, M.D.

8

DIRECTOR Elissa J. Schwartz, PhD

9

DIRECTOR Harold H. Shlevin, Ph.D

10

DIRECTOR Richard E. Uihlein

11

DIRECTOR Richard A. Zordani

12

To vote on a non-binding advisory resolution to approve the compensation paid to Galectins named executive officers, as disclosed in the proxy statement accompanying this letter.

13

To recommend, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensation.

14

To ratify the selection by the Audit Committee of the Board of Directors of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.